6/4
05:00 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/30
06:47 am
prax
This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate [Yahoo! Finance]
Medium
Report
This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate [Yahoo! Finance]
5/17
08:14 am
prax
Praxis Precision Medicines to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Praxis Precision Medicines to Participate in Upcoming Investor Conferences [Yahoo! Finance]
5/17
08:00 am
prax
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Low
Report
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
5/16
02:13 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $150.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $150.00 price target on the stock.
5/14
08:06 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
5/13
07:46 am
prax
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors [Yahoo! Finance]
Medium
Report
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors [Yahoo! Finance]
5/13
07:00 am
prax
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Medium
Report
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
5/10
08:00 am
prax
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
Low
Report
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
5/3
04:45 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/1
07:15 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $117.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $117.00 price target on the stock.
4/26
08:11 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
4/12
08:14 am
prax
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]
4/12
08:00 am
prax
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Low
Report
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
4/11
01:34 pm
prax
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why [Yahoo! Finance]
4/5
09:09 am
prax
Praxis Precision Medicines to Participate in Upcoming April Conferences [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines to Participate in Upcoming April Conferences [Yahoo! Finance]
4/5
09:00 am
prax
Praxis Precision Medicines to Participate in Upcoming April Conferences
Medium
Report
Praxis Precision Medicines to Participate in Upcoming April Conferences
4/2
05:00 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28
10:34 am
prax
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates [Yahoo! Finance]
3/28
12:20 am
prax
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
Medium
Report
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
3/27
04:01 pm
prax
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Medium
Report
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
3/27
12:16 pm
prax
Praxis (PRAX) Surges on Positive Epilepsy Study Results [Yahoo! Finance]
Low
Report
Praxis (PRAX) Surges on Positive Epilepsy Study Results [Yahoo! Finance]
3/26
01:56 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Jefferies Financial Group Inc. from $75.00 to $128.00. They now have a "buy" rating on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Jefferies Financial Group Inc. from $75.00 to $128.00. They now have a "buy" rating on the stock.
3/26
01:46 pm
prax
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing [Seeking Alpha]
Medium
Report
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing [Seeking Alpha]
3/26
12:26 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.